Linda Mahjoubi

Linda Mahjoubi

UNVERIFIED PROFILE

Are you Linda Mahjoubi?   Register this Author

Register author
Linda Mahjoubi

Linda Mahjoubi

Publications by authors named "Linda Mahjoubi"

Are you Linda Mahjoubi?   Register this Author

11Publications

669Reads

40Profile Views

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 11 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.011DOI Listing
November 2018

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Eur J Cancer 2017 11 13;85:155-157. Epub 2017 Sep 13.

Drug Development Department (DITEP), Gustave Roussy, and University Paris-Sud, Villejuif, France; INSERM U981, Gustave Roussy, University Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.049DOI Listing
November 2017

New insights into the role of EMT in tumor immune escape.

Mol Oncol 2017 07 27;11(7):824-846. Epub 2017 Jun 27.

INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, Fac. de médecine - Univ. Paris-Sud, University Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496499PMC
July 2017

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Eur J Cancer 2016 09 21;65:33-42. Epub 2016 Jul 21.

Université Paris-Saclay, Paris, France; Gustave Roussy, Université Paris-Saclay, Drug Development Department, Villejuif, F-94805, France; Gustave Roussy, Université Paris-Saclay, INSERM U981, Predictive Biomarkers and New Therapeutic Strategies in Oncology, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.05.031DOI Listing
September 2016

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.

Invest New Drugs 2016 06 18;34(3):397-8. Epub 2016 Feb 18.

Drug development Department (DITEP), Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10637-016-03
Web Search
http://link.springer.com/10.1007/s10637-016-0332-0
Publisher Site
http://dx.doi.org/10.1007/s10637-016-0332-0DOI Listing
June 2016